Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD2 | O60906 | 2/20 | 1.00 |
| ▸ | SMPD1 | P17405 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.59 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.59 |
| ▸ | UGCG | Q16739 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7770736 | 0.81 | ASAH1 (0.73) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL7773486 | 0.80 | ALDH1A1 (0.71) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL8341808 | 0.80 | ALDH1A1 (0.71) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL7773484 | 0.80 | ALDH1A1 (0.71) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL7099901 | 0.76 | ASAH1 (0.65) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL7101185 | 0.76 | ASAH1 (0.65) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL7790480 | 0.76 | ASAH1 (0.65) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL13930314 | 0.75 | ASAH1 (1.00) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL8340882 | 0.75 | ASAH1 (1.00) | SMPD2SMPD1ALDH1A1ASAH1ACER2 | |
| SCHEMBL13930311 | 0.75 | ASAH1 (1.00) | SMPD2SMPD1ALDH1A1ASAH1ACER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570633-B2 | Preparation method for CDK4/6 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2026-03-10 | — | — | US | claimed |
| US-20230331699-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-10-19 | — | — | US | claimed |
| EP-4159728-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-04-05 | — | — | EP | claimed |
| CN-115768763-A | Preparation method of CDK4/6 inhibitor | 正大天晴药业集团股份有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-12570633-B2 | Preparation method for CDK4/6 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2026-03-10 | — | — | US | disclosed |
| EP-4653841-A2 | METHOD AND APPARATUS FOR SELECTIVE TREATMENT OF BIOLOGICAL TISSUE | The General Hospital Corporation (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250352065-A1 | FEEDBACK DETECTION FOR A TREATMENT DEVICE | Avava, Inc. | 2025-11-20 | — | — | US | disclosed |
| EP-3559976-B1 | METHOD AND APPARATUS FOR SELECTIVE TREATMENT OF BIOLOGICAL TISSUE | MASSACHUSETTS GEN HOSPITAL (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12383143-B2 | Feedback detection for a treatment device | Avava, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12336756-B2 | Method and apparatus for selective treatment of biological tissue | THE GENERAL HOSPITAL CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-12239438-B2 | Blood analysis devices, systems and methods | Quantum Innovation Australia Pty Ltd (AU) | 2025-03-04 | — | — | US | disclosed |
| CN-115670643-B | Feedback detection for therapeutic devices | 阿瓦瓦公司 | 2024-11-22 | — | — | CN | disclosed |
| US-11457816-B2 | Feedback detection for a treatment device | Avava, Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11426074-B2 | Feedback detection for a treatment device | Avava, Inc. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220265169-A1 | BLOOD ANALYSIS DEVICES, SYSTEMS AND METHODS | Quantum Innovation Australia Pty Ltd (AU) | 2022-08-25 | — | — | US | disclosed |
| CN-110800081-B | Method and apparatus for selective treatment of biological tissue | 通用医疗公司 | 2022-07-26 | — | — | CN | disclosed |
| EP-3576914-B1 | A COMPOSITE MATERIAL AND COMPOSITE PRODUCT | STORA ENSO OYJ (FI) | 2022-06-29 | — | — | EP | disclosed |
| US-11344358-B2 | Apparatus for selective treatment of tissue | Avava, Inc. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220133407-A1 | METHOD AND APPARATUS FOR SELECTIVE TREATMENT OF BIOLOGICAL TISSUE | THE GENERAL HOSPITAL CORPORATION | 2022-05-05 | — | — | US | disclosed |
| CN-114213813-A | High-temperature-resistant impact-resistant transparent resin and preparation method and application thereof | 金发科技股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570633-B2 | Preparation method for CDK4/6 inhibitor | CDK4, CDK6, CDK8 | SMPD2 2897/4885SMPD1 2647/4885ALDH1A1 2188/4885 |
| US-20230331699-A1 | PREPARATION METHOD FOR CDK4/6 INHIBITOR | CDK4, CDK6, CDK2 | SMPD2 4554/4885SMPD1 4435/4885ALDH1A1 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.